Abstract

Microbial natural products (NPs) are a major source of pharmacological agents. Most NPs are synthesized from specific biosynthetic gene clusters (BGCs). With the rapid increase of sequenced microbial genomes, large numbers of NP BGCs have been discovered, regarded as a treasure trove of novel bioactive compounds. However, many NP BGCs are silent in native hosts under laboratory conditions. In order to explore their therapeutic potential, a main route is to activate these silent NP BGCs in heterologous hosts. To this end, the first step is to accurately and efficiently capture these BGCs. In the past decades, a large number of effective technologies for cloning NP BGCs have been established, which has greatly promoted drug discovery research. Herein, we describe recent advances in strategies for BGC cloning, with a focus on the preparation of high-molecular-weight DNA fragment, selection and optimization of vectors used for carrying large-size DNA, and methods for assembling targeted DNA fragment and appropriate vector. The future direction into novel, universal, and high-efficiency methods for cloning NP BGCs is also prospected.

Highlights

  • Natural products (NPs) produced by microbes are a major source of pharmacological agents and industrially useful compounds

  • It should be noted that, in order to ensure a high efficiency for the linear-linear homologous recombination (LLHR)-mediated cloning method, genomic DNA must be cleaved by unique restriction enzymes near the 5’ and 3’ ends of target biosynthetic gene clusters (BGCs)

  • Exploring new antibiotics to combat against emerging drug resistance as well as the identification of new lead drugs for the treatment of various diseases are of utmost necessity

Read more

Summary

Introduction

Natural products (NPs) produced by microbes are a major source of pharmacological agents and industrially useful compounds. A major drawback is the problematic identification of naturally existing unique restriction enzyme recognition sites on both sides of the target BGCs. artificial insertion of a specific DNA sequence into the genome via homologous recombination (HR) is a prerequisite, limiting the application of this method in intractable strains.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.